Skip to main content

Renal Diseases Drug Development Pipeline Review 2018 – AdAlta , Allena Pharmaceuticals , apceth Biopharma , Arch Biopartners , Astellas Pharma , AstraZeneca , Bayer

This report provides an overview of the pipeline landscape for renal diseases. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for chronic kidney disease (chronic renal failure), kidney fibrosis, polycystic kidney disease and end-stage kidney disease (end-stage renal disease), and features dormant and discontinued products. Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of the feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol. There are 58 products in development for this indication.
Some of Key Players are: 
AdAlta , Allena Pharmaceuticals , apceth Biopharma , Arch Biopartners , Astellas Pharma , AstraZeneca , Bayer , BiOrion Technologies , Boehringer Ingelheim , Boryung Pharmaceutical , Celgene , Certa Therapeutics , Conatus Pharmaceuticals , Corvidia Therapeutics , DiaMedica Therapeutics , Dimerix Bioscience , DiscoveryBiomed , DURECT C, Epigen Biosciences , Galectin Therapeutics , GenKyoTex , GNI Group , iBio Inc, IC-MedTech , Ipsen , Isarna Therapeutics , KBP BioSciences , Kidney Fibrosis, Klotho Therapeutics , Les Laboratoires Servier ,
Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant. There are 49 products in development for this indication.
Polycystic kidney disease is a disorder in which clusters of cysts develop primarily within the kidneys. Polycystic kidney disease symptoms may include high blood pressure, back or side pain, headache, blood in the urine, frequent urination and kidney failure. The predisposing factors include age and family history. Treatment includes antihypertensive drugs and diuretics. There are 26 products in development for this indication.
End-stage kidney disease is the complete or almost complete failure of the kidneys to work. Symptoms include inability to urinate, fatigue, headaches, loss of appetite, nausea and vomiting, bone pain, confusion and difficulty concentrating. The risk factors include polycystic kidney disease, Alport syndrome, interstitial nephritis and certain autoimmune conditions, such as lupus. Treatment includes dialysis or kidney transplant. There are five products in development for this indication.
Molecular targets in development for renal diseases include growth factor receptors, chemokines and kinases. Companies operating in this pipeline space include Angion Biomedica, Prolong Pharmaceuticals and Novartis.
Scope
- Which companies are the most active within each pipeline-
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication-
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies-
- What are the most important R&D milestones and data publications to have happened in this disease area-
 Table of Contents
1 Table of Contents 
1.1 List of Tables
1.2 List of Figures
2 Introduction 
2.1 Renal Diseases Report Coverage
2.2 Chronic Kidney Disease (Chronic Renal Failure) - Overview
2.3 Kidney Fibrosis - Overview
2.4 Polycystic Kidney Disease - Overview
2.5 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview
3 Therapeutics Development 
3.1 Chronic Kidney Disease (Chronic Renal Failure)
3.2 Kidney Fibrosis
3.3 Polycystic Kidney Disease
3.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
4 Therapeutics Assessment 
4.1 Chronic Kidney Disease (Chronic Renal Failure)
4.2 Kidney Fibrosis
4.3 Polycystic Kidney Disease
4.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
5 Companies Involved in Therapeutics Development 
5.1 Chronic Kidney Disease (Chronic Renal Failure)
5.2 Kidney Fibrosis
5.3 Polycystic Kidney Disease
5.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
6 Dormant Projects 
6.1 Chronic Kidney Disease (Chronic Renal Failure)
6.2 Kidney Fibrosis
6.3 Polycystic Kidney Disease
6.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
7 Discontinued Products 
7.1 Chronic Kidney Disease (Chronic Renal Failure)
7.2 Kidney Fibrosis
7.3 Polycystic Kidney Disease
7.4 End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)
8 Product Development Milestones 
8.1 Chronic Kidney Disease (Chronic Renal Failure)
8.2 Kidney Fibrosis
8.3 Polycystic Kidney Disease
9 Appendix 
9.1 Methodology
9.2 Coverage
9.3 Secondary Research
9.4 Primary Research
9.5 Expert Panel Validation
9.6 Contact Us
9.7 Disclaimer
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com
Labels:

Comments

Post a Comment

Popular posts from this blog

High-Density Interconnect (HDI) PCB Market Growth 2018-2025 Leading Key Players – Compeq Manufacturing , TTM Technologies, Unimicron, AT&S, Ibiden Group, SEMCO

The global HDI PCB market was valued at $9,491.0 million in 2017 and is projected to reach $22,258.8 million by 2025, registering a CAGR of 11.1% from 2018 to 2025. A high-density interconnect (HDI) is a fastest growing technology used in the printed circuit board (PCB), which have higher wiring density per unit as compared to the conventional circuit boards. These HDI PCBs have finer lines and spaces (? 100 ?m), smaller vias (? 150 ?m), and capture pads (? 400 ?m). Moreover, HDI PCBs have a relatively higher connection pad density over conventional PCBs that is over 20 pads/cm2. Hence, they are widely adopted in the consumer electronics sector and have a high growth potential in the automotive industry. The key players profiled in the report include: Compeq Manufacturing , TTM Technologies, Unimicron, AT&S, Ibiden Group, SEMCO, Unitech Printed Circuit Board Corp., Tripod Technology Corp., DAP Corporation and Meiko. Get sample copy of “High-Density Interconnect (HDI) PCB ...
Post a Comment
Read more

Medical Arrhythmia Monitoring Devices Market Business Development Strategies 2019 by Major Key Players – GE Healthcare , Medtronic , Abbott Laboratories (St. Jude Medical)

Arrhythmia monitoring refers to tests physicians use to identify the type and the cause of irregular heart rhythms. Many arrhythmias occur infrequently, so to record the heart’s electrical activity under real-world conditions, physicians use continuous monitor recording, also called ambulatory electrocardiography. Medical Arrhythmia Monitoring Devices Market report also provide a thorough understanding of the cutting-edge competitive analysis of the emerging market trends along with the drivers, restraints, challenges, and opportunities in the Medical Arrhythmia Monitoring Devices Market to offer worthwhile insights and current scenario for making right decision. The report covers the prominent players in the market with detailed SWOT analysis, financial overview, and key developments of the products/services from the past three years. Moreover, the report also offers a 360º outlook of the market through the competitive landscape of the global industry player and helps the companie...
Post a Comment
Read more

LONG CHAIN DIBASIC ACIDS MARKET EMERGING TREND, TECHNOLOGICAL GROWTH, BUSINESS GROWTH STATISTICS AND HIGH DEMAND

A dibasic acid is an acid that has two oxygen ions to donate to a base in an acid-base reaction. Therefore, a dibasic molecule has two replaceable hydrogen atoms. The most common example is sulfuric acid (H2SO4). Long Chain Dibasic Acids Market report provides in-depth statistics and analysis available on the market status of the Long Chain Dibasic Acids Manufacturers and is a valuable method of obtaining guidance and direction for companies and business enterprise insider considering the Long Chain Dibasic Acids market. It contains the analysis of drivers, challenges, and restraints impacting the industry. Long Chain Dibasic Acids Market report also provide a thorough understanding of the cutting-edge competitive analysis of the emerging market trends along with the drivers, restraints, challenges, and opportunities in the Long Chain Dibasic Acids Market to offer worthwhile insights and current scenario for making right decision. The report covers the prominent players in the mark...
Post a Comment
Read more